Company intelligence / Profile preview

Rejuvenate

Belgium

Ownership: Private
Development stage: Other

Overview

Rejuvenate Biomed is a clinical-stage biotech developing AI-designed fixed-dose combinations of existing approved drugs to target multiple aging pathways. Its lead program RJx-01 (galantamine + metformin) has completed a Phase 1b study in older men with cast-induced muscle atrophy, showing safety, tolerability, good bioavailability, and signals of improved strength recovery, leg acceleration, and fatigue resistance versus placebo. A Phase 2 double-blind, placebo-controlled trial in COPD-related sarcopenia is underway, primarily assessing safety and secondarily physical function and muscle strength.[1][6]

Therapeutic areas: PulmonologyNeurologyOtherMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

National Institute for Health and Care Research Leicester Biomedical Research CentreUniversity of LeicesterWellcome LeapTemasek Trust

Beyond the preview

Go deeper on Rejuvenate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rejuvenate.

Explore the full profile